文献速递中毒与环境急症重症综合管理与镇静镇痛

连续肾脏替代治疗期间甲吡唑的剂量:一项观察性研究

Fomepizole dosing during continuous renal replacement therapy - an observational study.
PubMed 文献 · Clin Toxicol (Phila) · 2021-09-29

这项前瞻性观察研究纳入10例接受甲吡唑和CRRT的成人中毒患者,其中7例CVVHD、3例CVVHDF。CRRT期间甲吡唑中位饱和/筛系数为0.85,透析清除率28 mL/min。结论认为CRRT期间甲吡唑维持剂量较间歇性血液透析减半是安全的。

要点

  • 甲吡唑在CRRT期间被清除,中位饱和/筛系数0.85,透析清除率28 mL/min。
  • 研究纳入10例成人中毒患者,7例CVVHD、3例CVVHDF,均为前瞻性观察。
  • 该减量方案基于2016年药代动力学数据建议,本研究验证其安全性。
  • 甲吡唑价格高、可及性有限,减量方案在群体中毒事件中有助于节约药物。

适用人群与场景

  • 接受甲吡唑和CRRT治疗的成人中毒患者(甲醇或乙二醇中毒)。
  • 研究纳入7例CVVHD和3例CVVHDF患者。

诊断标准与关键阈值

  • 甲吡唑最低有效血浆浓度为10 µmol/L。

处置流程与药物剂量

  • CRRT期间甲吡唑维持剂量较间歇性血液透析减半(具体剂量原文未提及)。
  • 目标维持血浆甲吡唑浓度高于10 µmol/L。
  • 原文未提及给药途径、频次或疗程的具体细节。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 前瞻性观察研究,纳入10例成人患者(7例CVVHD,3例CVVHDF)。
  • 甲吡唑中位饱和/筛系数0.85,透析清除率28 mL/min。
  • 结论认为CRRT期间甲吡唑维持剂量减半方案安全。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 样本量小(10例),单中心设计,无对照组。

对床旁实践的改变

  • CRRT期间甲吡唑维持剂量可较间歇性血液透析减半,同时监测血浆浓度高于10 µmol/L。
  • 该方案适用于接受CRRT的成人甲醇或乙二醇中毒患者。
  • 需注意样本量小,结论需更大规模研究验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Fomepizole is the preferred antidote for treatment of methanol and ethylene glycol poisoning, acting by inhibiting the formation of the toxic metabolites. Although very effective, the price is high and the availability is limited. Its availability is further challenged in situations with mass poisonings. Therefore, a 50% reduced maintenance dose for fomepizole during continuous renal replacement therapy (CRRT) was suggested in 2016, based on pharmacokinetic data only. Our aim was to study whether this new dosing for fomepizole during CRRT gave plasma concentrations above the required 10 µmol/L. Secondly, we wanted to study the elimination kinetics of fomepizole during CRRT, which has never been studied before.

METHODS: Prospective observational study of adult patients treated with fomepizole and CRRT. We collected samples from arterial line (pre-filter) = plasma concentration, post-filter and dialysate for fomepizole measurements. Fomepizole was measured using high-pressure liquid chromatography with a reverse phase column.

RESULTS: Ten patients were included in the study. Seven were treated with continuous veno-venous hemodialysis (CVVHD) and three with continuous veno-venous hemodiafiltration (CVVHDF). Ninety-eight percent of the plasma samples were above the minimum plasma concentration of 10 µmol/L. Fomepizole was removed during CRRT with a median saturation/sieving coefficient of 0.85 and dialysis clearance of 28 mL/min.

CONCLUSION: Fomepizole was eliminated during CCRT. The new dosing recommendations for fomepizole and CRRT appeared safe, by maintaining the plasma concentration above the minimum value of 10 µmol/L. Based on these data, the fomepizole maintenance dose during CRRT could be reduced to half as compared to intermittent hemodialysis.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Lao YE, Vartdal T, Froeyshov S, et al. Fomepizole dosing during continuous renal replacement therapy - an observational study. Clin Toxicol (Phila). 2021. PMID: 34585641. doi:10.1080/15563650.2021.1980581

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。